PMID- 24335764
OWN - NLM
STAT- MEDLINE
DCOM- 20150421
LR  - 20220317
IS  - 1476-5497 (Electronic)
IS  - 0307-0565 (Linking)
VI  - 38
IP  - 9
DP  - 2014 Sep
TI  - Kefir improves fatty liver syndrome by inhibiting the lipogenesis pathway in 
      leptin-deficient ob/ob knockout mice.
PG  - 1172-9
LID - 10.1038/ijo.2013.236 [doi]
AB  - OBJECTIVE: Fatty liver disease is commonly associated with obesity, insulin 
      resistance and diabetes. Severe fatty liver is sometimes accompanied by 
      steatohepatitis and may lead to the development of hepatocellular carcinoma. At 
      present, there is no effective treatment for non-alcoholic fatty liver disease 
      (NAFLD); thus, recent investigations have focused on developing effective 
      therapeutics to treat this condition. This study aimed to evaluate the effects of 
      kefir on the hepatic lipid metabolism of ob/ob mice, which are commonly used to 
      model fatty liver disease. RESULTS: In this study, we used leptin 
      receptor-deficient ob/ob mice as an animal disease model of NAFLD. Six-week-old 
      ob/ob mice were orally administered the dairy product kefir (140 mg kg(-1) of 
      body weight (BW) per day) for 4 weeks. The data demonstrated that kefir improved 
      fatty liver syndrome on BW, energy expenditure and basal metabolic rate by 
      inhibiting serum glutamate oxaloacetate transaminase (GOT) and glutamate pyruvate 
      transaminase (GPT) activities (P<0.05) and by decreasing the triglyceride (TG) 
      and total cholesterol (TC) contents of the liver (P<0.05). Oral kefir 
      administration also significantly reduced the macrovesicular fat quantity in 
      liver tissue. In addition, kefir markedly decreased the expression of the genes 
      sterol regulatory element-binding protein 1 (SREBP1), fatty acid synthase (FAS) 
      and acetyl-CoA carboxylase (ACC) (P<0.05) but not the expression of peroxisome 
      proliferator-activated receptor alpha (PPARalpha) or hepatic carnitine 
      palmitoyltransferase-1alpha (CPT1alpha) in the livers of ob/ob mice. CONCLUSION: On the 
      basis of these results, we conclude that kefir improves NAFLD on BW, energy 
      expenditure and basal metabolic rate by inhibiting the lipogenesis pathway and 
      that kefir may have the potential for clinical application to the prevention or 
      treatment of NAFLD.
FAU - Chen, H-L
AU  - Chen HL
AD  - Department of Bioresources, Da-Yeh University, Changhwa, Taiwan.
FAU - Tung, Y-T
AU  - Tung YT
AD  - Department of Life Sciences, Agricultural Biotechnology Center, National Chung 
      Hsing University, Taichung, Taiwan.
FAU - Tsai, C-L
AU  - Tsai CL
AD  - Department of Life Sciences, Agricultural Biotechnology Center, National Chung 
      Hsing University, Taichung, Taiwan.
FAU - Lai, C-W
AU  - Lai CW
AD  - Department of Life Sciences, Agricultural Biotechnology Center, National Chung 
      Hsing University, Taichung, Taiwan.
FAU - Lai, Z-L
AU  - Lai ZL
AD  - Department of Life Sciences, Agricultural Biotechnology Center, National Chung 
      Hsing University, Taichung, Taiwan.
FAU - Tsai, H-C
AU  - Tsai HC
AD  - 1] Department of Life Sciences, Agricultural Biotechnology Center, National Chung 
      Hsing University, Taichung, Taiwan [2] Department of Surgery, Taichung Hospital, 
      Ministry of Health and Welfare, Taichung, Taiwan.
FAU - Lin, Y-L
AU  - Lin YL
AD  - 1] Department of Life Sciences, Agricultural Biotechnology Center, National Chung 
      Hsing University, Taichung, Taiwan [2] Department of Surgery, Taichung Veterans 
      General Hospital, Taichung, Taiwan.
FAU - Wang, C-H
AU  - Wang CH
AD  - Department of Biological Science and Technology, National Chiao Tung University, 
      Hsinchu, Taiwan.
FAU - Chen, C-M
AU  - Chen CM
AD  - 1] Department of Life Sciences, Agricultural Biotechnology Center, National Chung 
      Hsing University, Taichung, Taiwan [2] Rong Hsing Research Center for 
      Translational Medicine and the iEGG Center, National Chung Hsing University, 
      Taichung, Taiwan.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20131216
PL  - England
TA  - Int J Obes (Lond)
JT  - International journal of obesity (2005)
JID - 101256108
RN  - 0 (Biomarkers)
RN  - 0 (Receptors, Leptin)
RN  - 0 (Srebf1 protein, mouse)
RN  - 0 (Sterol Regulatory Element Binding Protein 1)
SB  - IM
MH  - Animals
MH  - Basal Metabolism
MH  - Biomarkers/metabolism
MH  - Blotting, Western
MH  - Cultured Milk Products/*metabolism
MH  - Disease Models, Animal
MH  - Energy Metabolism
MH  - Gene Expression Regulation
MH  - Lipid Metabolism
MH  - Liver/*metabolism
MH  - Mice
MH  - Mice, Knockout
MH  - Mice, Obese
MH  - Non-alcoholic Fatty Liver Disease/diet therapy/*metabolism/physiopathology
MH  - Organ Size
MH  - Receptors, Leptin/deficiency
MH  - Signal Transduction
MH  - Sterol Regulatory Element Binding Protein 1/*metabolism
EDAT- 2013/12/18 06:00
MHDA- 2015/04/22 06:00
CRDT- 2013/12/17 06:00
PHST- 2013/06/08 00:00 [received]
PHST- 2013/11/25 00:00 [revised]
PHST- 2013/11/26 00:00 [accepted]
PHST- 2013/12/17 06:00 [entrez]
PHST- 2013/12/18 06:00 [pubmed]
PHST- 2015/04/22 06:00 [medline]
AID - ijo2013236 [pii]
AID - 10.1038/ijo.2013.236 [doi]
PST - ppublish
SO  - Int J Obes (Lond). 2014 Sep;38(9):1172-9. doi: 10.1038/ijo.2013.236. Epub 2013 
      Dec 16.